ClinicalTrials.gg
CompletedNCT00195728Updated Jan 19, 2011

Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain

A Phase 3 interventional study of Hydrocodone/Acetaminophen on Extended Release in Moderate to Severe Chronic, Non-malignant Pain, sponsored by Abbott. Completed at 76 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-19.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
431
Allocation
Non-randomized
Ages
21 Years to 75 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety of Vicodin CR (combination opioid and acetaminophen containing product) in patients with chronic pain due to osteoarthritis or low back pain.

02

Conditions studied

  • Moderate to Severe Chronic, Non-malignant Pain

Keywords

  • Hydrocodone/Acetaminophen
  • Vicodin CR
03

In context

Lead sponsor

Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and Females between 21 and 75 years of age

    • Females must be of non-child bearing potential or practicing birth control
  • Moderate to severe mechanical low back pain OR moderate to severe OA of the hip or knee pain
  • Require medicine for pain the majority of days in the previous 3 months, AND for at least 4 days per week, during the previous 4 weeks.
  • Pain is not controlled with non-opioid analgesics or is contraindicated due to side effects and/or currently receiving opioid therapy equivalent to 40 mg/day of morphine or less

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or breastfeeding females or females planning to become pregnant during the course of the study
  • Incapacitated, bedridden, or confined to a wheelchair permitting little or no self-care
  • Injury to the index joint or lower back within 3 months of study
  • History of any of the following:

    • Major surgery to the lower back within the last 5 years OR
    • Joint replacement/reconstruction to the index joint OR
    • Arthroscopic or open surgery to the index joint within the last year OR
    • Any surgery within 3 months of study
  • Osteoporotic compression fracture, traumatic vertebral fracture or invasive intervention for low back pain within the last year.
  • Abnormal neurological exam, or lower extremity symptoms characteristic of neurogenic pain
  • History of inflammatory or infectious arthritis, tumors or infections of spinal cord, spinal stenosis, fibromyalgia or other chronic painful condition
  • Severe gastrointestinal narrowing
  • History of peritonitis, cystic fibrosis, chronic intestinal eudoobstruction, or Meckel's diverticulum.
  • Has received

    • Oral, intramuscular (IM), intravenous (IV) or non-index joint intra- articular corticosteroids within 1 month of study OR
    • Intra-articular corticosteroids at the index joint or epidural corticosteroids to the lower back region within 2 months of study, OR
    • Viscosupplementation therapy to index joint within 4 months of study
  • History of drug (licit or illicit) or alcohol abuse/addiction
  • Positive result for drugs of abuse at screening.
  • Chronic heavy drinker, consuming more than 4 alcoholic drinks per day.
  • History of malnutrition or starvation or is likely to fast for more than 4 consecutive days during the course of the study.
  • Medical condition or illness other than OA/CLBP, which is not well controlled
  • History of allergic reaction or a clinically significant sensitivity or intolerance to opioids and/or acetaminophen.
  • Newly diagnosed medical condition
  • Clinically significant infection/injury/illness within 1 month of study
  • Receiving systemic chemotherapy, or has an active malignancy of any type, or has been diagnosed with cancer within the past 5 years. Basal cell carcinoma of the skin that has been successfully treated will be permitted.
  • Known or suspected history of Human Immunodeficiency Virus.
  • Positive Hepatitis Screen
  • Clinically significant abnormalities in clinical chemistry, hematology or urinalysis
  • Received any investigational drug within 1 month of study
  • History of major psychiatric disorder
  • Active or uncontrolled seizure disorder.
  • Requires treatment with monoamine oxidase inhibitors (MAOIs), or tricyclic antidepressants during the course of the study.
  • Surgical procedure planned, or scheduled during the course of this study.
  • Ongoing workman's compensation claim or litigation.
  • Previous participation in the M03-666 study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
431 participants (actual)

Study arms

  • Experimental
    hydrocodone/acetaminophen extended release

    Drug: Hydrocodone/Acetaminophen on Extended Release

Interventions

  • DrugHydrocodone/Acetaminophen on Extended Release

    2 tablets twice daily

    Also known as: ABT-712

06

What researchers measure

Primary outcomes

  1. Safety evaluation

    Long term safety

    Time frame: 56 weeks

07

Study locations

76 sites
  • Site Ref # / Investigator 1696
    Huntsville, Alabama 35801, United States
  • Site Reference # / Investigator 1729
    Chandler, Arizona 85224, United States
  • Site Reference # / Investigator 1702
    Mesa, Arizona 85210, United States
  • Site Reference # / Investigator 1745
    Peoria, Arizona 85381, United States
  • Site Ref # / Investigator 1697
    Tempe, Arizona 85282, United States
  • Site Ref # / Investigator 1818
    Tempe, Arizona 85282, United States
  • Site Reference # / Investigator 1795
    Tucson, Arizona 85741, United States
  • Site Ref # / Investigator 2555
    Carmichael, California 95608, United States
  • Site Reference # / Investigator 1688
    Fair Oaks, California 95628, United States
  • Site Reference # / Investigator 1790
    Pasadena, California 21122, United States
  • Site Reference # / Investigator 1735
    San Diego, California 92108, United States
  • Site Reference # / Investigator 1775
    San Luis Obispo, California 93401, United States
  • Site Ref # / Investigator 1742
    Santa Ana, California 92705, United States
  • Site Ref # / Investigator 1754
    Tarzana, California 91356, United States
  • Site Reference # / Investigator 1700
    Whittier, California 90601, United States
  • Site Reference # / Investigator 1690
    Colorado Springs, Colorado 80904, United States
  • Site Ref # / Investigator 1713
    Littleton, Colorado 80120, United States
  • Site Ref # / Investigator 1711
    Bristol, Connecticut 06010, United States
  • Site Reference # / Investigator 1723
    Clearwater, Florida 33756, United States
  • Site Ref # / Investigator 1813
    Clearwater, Florida 33761, United States
  • Site Reference # / Investigator 1718
    DeLand, Florida 32720, United States
  • Site Reference # / Investigator 1819
    Longwood, Florida 32779, United States
  • Site Reference # / Investigator 1809
    Miami, Florida 33156, United States
  • Site Reference # / Investigator 1738
    Miami, Florida 33173, United States
  • Site Ref # / Investigator 1716
    Orlando, Florida 32806, United States
  • Site Reference # / Investigator 1755
    Palm Harbor, Florida 34684, United States
  • Site Ref # / Investigator 1814
    Pembroke Pines, Florida 33024, United States
  • Site Reference # / Investigator 1737
    Plantation, Florida 33324, United States
  • Site Reference # / Investigator 1747
    St. Petersburg, Florida 33702, United States
  • Site Reference # / Investigator 1744
    Arlington Heights, Illinois 60005, United States
  • Site Reference # / Investigator 1691
    Chicago, Illinois 60612, United States
  • Site Reference # / Investigator 1714
    Evansville, Indiana 47714, United States
  • Site Ref # / Investigator 1739
    Metairie, Louisiana 70006, United States
  • Site Reference # / Investigator 1810
    Owings Mills, Maryland 21117, United States
  • Site Ref # / Investigator 1707
    Fall River, Massachusetts 02720, United States
  • Site Reference # / Investigator 1743
    Wellesley Hills, Massachusetts 02481-2106, United States
  • Site Ref # / Investigator 1792
    Jackson, Mississippi 39202, United States
  • Site Reference # / Investigator 1721
    St Louis, Missouri 63117, United States
  • Site Ref # / Investigator 1812
    St Louis, Missouri 63141, United States
  • Site Reference # / Investigator 2424
    St Louis, Missouri 63141, United States
  • Site Ref # / Investigator 1722
    Omaha, Nebraska 68134, United States
  • Site Ref # / Investigator 1774
    Omaha, Nebraska 68134, United States
  • Site Reference # / Investigator 1789
    Omaha, Nebraska 68134, United States
  • Site Reference # / Investigator 1705
    Las Vegas, Nevada 89104, United States
  • Site Reference # / Investigator 1791
    Las Vegas, Nevada 89123, United States
  • Site Reference # / Investigator 1701
    Medford, New Jersey 08055, United States
  • Site Reference # / Investigator 2461
    Trenton, New Jersey 08629-1986, United States
  • Site Reference # / Investigator 1726
    Binghamton, New York 13901, United States
  • Site Reference # / Investigator 1815
    New York, New York 10022, United States
  • Site Reference # / Investigator 1708
    Charlotte, North Carolina 28210, United States
  • Site Ref # / Investigator 1730
    Monroe, North Carolina 28112, United States
  • Site Reference # / Investigator 1741
    Raleigh, North Carolina 27609, United States
  • Site Reference # / Investigator 1689
    Cincinnati, Ohio 45227, United States
  • Site Ref # / Investigator 1694
    Cincinnati, Ohio 45236, United States
  • Site Ref # / Investigator 1816
    Cleveland, Ohio 44122, United States
  • Site Reference # / Investigator 1715
    Oklahoma City, Oklahoma 73103, United States
  • Site Reference # / Investigator 2423
    Portland, Oregon 97239, United States
  • Site Reference # / Investigator 1794
    Beaver, Pennsylvania 15009, United States
  • Site Reference # / Investigator 1749
    Duncansville, Pennsylvania 16635, United States
  • Site Reference # / Investigator 1752
    Erie, Pennsylvania 16508-1256, United States
  • Site Reference # / Investigator 1709
    Mechanicsburg, Pennsylvania 17055, United States
  • Site Reference # / Investigator 1757
    Cordova, Tennessee 38018, United States
  • Site Reference # / Investigator 1727
    Selmer, Tennessee 38375, United States
  • Site Ref # / Investigator 1692
    Austin, Texas 78705, United States
  • Site Reference # / Investigator 1722
    Austin, Texas 78728, United States
  • Site Reference # / Investigator 2425
    Dallas, Texas 75235, United States
  • Site Reference # / Investigator 1699
    Fort Worth, Texas 76135, United States
  • Site Ref # / Investigator 1725
    Killeen, Texas 76543, United States
  • Site Reference # / Investigator 1710
    San Angelo, Texas 76904, United States
  • Site Reference # / Investigator 1686
    San Antonio, Texas 78209, United States
  • Site Reference # / Investigator 2426
    San Antonio, Texas 78217, United States
  • Site Reference # / Investigator 1808
    San Antonio, Texas 78229, United States
  • Site Reference # / Investigator 1732
    Salt Lake City, Utah 84102, United States
  • Site Reference # / Investigator 1740
    Salt Lake City, Utah 84109, United States
  • Site Ref # / Investigator 1733
    Norfolk, Virginia 23502-9921, United States
  • Site Reference # / Investigator 1719
    Virginia Beach, Virginia 23455, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 20, 2005
Start
Jun 2005
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
Jan 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00195728
Lead sponsor
Abbott
First posted
Sep 20, 2005
Start date
Jun 2005
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Jan 19, 2011

Study contacts

Rita Jain, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion